Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF Therapy
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF Therapy
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF Therapy
Submitted by
admin
on May 31, 2009 - 10:00am
Source:
Yahoo/BusinessWire
News Tags:
Elan
Tysabri
Chron's Disease
Headline:
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF Therapy
Do Not Allow Advertisers to Use My Personal information
